Catalog Home Page

BACE1 inhibition using 2’-OMePS steric blocking antisense oligonucleotides

Chakravarthy, M. and Veedu, R.N. (2019) BACE1 inhibition using 2’-OMePS steric blocking antisense oligonucleotides. Genes, 10 (9).

[img]
Preview
PDF - Published Version
Download (2MB) | Preview
Free to read: https://doi.org/10.3390/genes10090705
*No subscription required

Abstract

Amyloid beta-peptide is produced by the cleavage of amyloid precursor protein by two secretases, a β-secretase, beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and a γ-secretase. It has been hypothesised that partial inhibition of BACE1 in individuals with a high risk of developing Alzheimer’s disease may be beneficial in preventing cognitive decline. In this study, we report the development of a novel antisense oligonucleotide (AO) that could efficiently downregulate the BACE1 transcript and partially inhibit BACE1 protein. We designed and synthesised a range of 2’-OMethyl-modified antisense oligonucleotides with a phosphorothioate backbone across various exons of the BACE1 transcript, of which AO2, targeting exon 2, efficiently downregulated BACE1 RNA expression by 90%. The sequence of AO2 was later synthesised with a phosphorodiamidate morpholino chemistry, which was found to be not as efficient at downregulating BACE1 expression as the 2’-OMethyl antisense oligonucleotides with a phosphorothioate backbone variant. AO2 also reduced BACE1 protein levels by 45%. In line with our results, we firmly believe that AO2 could be used as a potential preventative therapeutic strategy for Alzheimer’s disease

Item Type: Journal Article
Murdoch Affiliation: Centre for Molecular Medicine and Innovative Therapeutics (CMMIT)
Publisher: MDPI
Copyright: © 2019 by the authors.
URI: http://researchrepository.murdoch.edu.au/id/eprint/51520
Item Control Page Item Control Page

Downloads

Downloads per month over past year